Treatment with BRAF inhibitors dabrafenib and vemurafenib reduced the expression of lipogenic enzymes including FASN in therapy responsive A375 and 451lu melanoma cell lines, but not in the isogenic therapy-resistant 451lu R, the resistant cell line M233 or the BRAF + MEK inhibitor resistant cell line D10 BMR, correlating with the effect of MAPKi on pERK and pMEK expression (Fig. 1g, Supplementary Figure S1j-l). This evidence concerns the gene EIF2AK3 and melanoma.